Here’s Why Ozempic And Mounjaro Rivals Won’t Topple Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
Experts told Forbes incumbents Novo Nordisk and Eli Lilly are unlikely to cede much ground to rival weight loss drugs eying their dominant positions, noting it takes far more than a good drug to succeed in the lucrative market.
Experts told Forbes incumbents Novo Nordisk and Eli Lilly are unlikely to cede much ground to rival weight loss drugs eying their dominant positions, noting it takes far more than a good drug to succeed in the lucrative market.
What's Your Reaction?
